{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:03:13Z","timestamp":1787169793274,"version":"build-2736575974"},"reference-count":47,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","geriatriconcology.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Geriatric Oncology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jgo.2026.102971","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T21:38:05Z","timestamp":1776289085000},"page":"102971","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Safety and effectiveness of immune checkpoint inhibitors in older adults with metastatic non-small cell lung cancer and pre-existing autoimmune disease \u2013 A SEER-Medicare study"],"prefix":"10.1016","volume":"17","author":[{"given":"Shrey","family":"Gohil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Whitney E.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghana","family":"Trivedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajender R.","family":"Aparasu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael L.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"22","key":"10.1016\/j.jgo.2026.102971_bb0005","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.jgo.2026.102971_bb0010","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S1470-2045(19)30167-6","article-title":"Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"West","year":"2019","journal-title":"Lancet Oncol"},{"issue":"24","key":"10.1016\/j.jgo.2026.102971_bb0015","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N Engl J Med."},{"issue":"21","key":"10.1016\/j.jgo.2026.102971_bb0020","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced non-small-cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.jgo.2026.102971_bb0025","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","article-title":"Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC","volume":"383","author":"Herbst","year":"2020","journal-title":"N Engl J Med."},{"issue":"10183","key":"10.1016\/j.jgo.2026.102971_bb0030","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.jgo.2026.102971_bb0035","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S1470-2045(20)30641-0","article-title":"First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial","volume":"22","author":"Paz-Ares","year":"2021","journal-title":"Lancet Oncol"},{"issue":"21","key":"10.1016\/j.jgo.2026.102971_bb0040","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.jgo.2026.102971_bb0045","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med."},{"issue":"10274","key":"10.1016\/j.jgo.2026.102971_bb0050","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/S0140-6736(21)00228-2","article-title":"Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial","volume":"397","author":"Sezer","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jgo.2026.102971_bb0055","article-title":"The efficacy and safety of immune checkpoint inhibitors in patients with cancer and preexisting autoimmune disease","volume":"11","author":"Tang","year":"2021","journal-title":"Front Oncol"},{"issue":"Suppl. 7","key":"10.1016\/j.jgo.2026.102971_bb0060","doi-asserted-by":"crossref","first-page":"vii59","DOI":"10.1093\/rheumatology\/kez308","article-title":"Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors","volume":"58","author":"Weinmann","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.jgo.2026.102971_bb0065","doi-asserted-by":"crossref","first-page":"121","DOI":"10.7326\/M17-2073","article-title":"Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: a systematic review","volume":"168","author":"Abdel-Wahab","year":"2018","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.jgo.2026.102971_bb0070","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.intimp.2018.06.001","article-title":"Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors","volume":"62","author":"Hargadon","year":"2018","journal-title":"Int Immunopharmacol"},{"issue":"7","key":"10.1016\/j.jgo.2026.102971_bb0075","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.cllc.2023.05.006","article-title":"Safety and efficacy of immune checkpoint inhibitors in cancer patients and preexisting autoimmune disease: a systematic review and Meta-analysis in non-small-cell lung cancer","volume":"24","author":"Aung","year":"2023","journal-title":"Clin Lung Cancer"},{"issue":"12","key":"10.1016\/j.jgo.2026.102971_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102687","article-title":"Immune checkpoint inhibitors therapies in patients with cancer and preexisting autoimmune diseases: a meta-analysis of observational studies","volume":"19","author":"Xie","year":"2020","journal-title":"Autoimmun Rev"},{"issue":"7","key":"10.1016\/j.jgo.2026.102971_bb0085","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2022.2145102","article-title":"Safety and efficacy of immune checkpoint inhibitors in advanced cancer patients with autoimmune disease: a meta-analysis","volume":"18","author":"Cai","year":"2022","journal-title":"Hum Vaccin Immunother"},{"issue":"19","key":"10.1016\/j.jgo.2026.102971_bb0090","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1200\/JCO.2017.77.0305","article-title":"Safety of programmed death-1 pathway inhibitors among patients with non-small-cell lung cancer and preexisting autoimmune disorders","volume":"36","author":"Leonardi","year":"2018","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.jgo.2026.102971_bb0095","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s00262-019-02321-z","article-title":"Pre-existing autoimmune disease and the risk of immune-related adverse events among patients receiving checkpoint inhibitors for cancer","volume":"68","author":"Kehl","year":"2019","journal-title":"Cancer Immunol Immunother"},{"issue":"6","key":"10.1016\/j.jgo.2026.102971_bb0100","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1634\/theoncologist.2018-0618","article-title":"Clinical outcomes of patients with advanced cancer and pre-existing autoimmune diseases treated with anti-programmed death-1 immunotherapy: a real-world transverse study","volume":"24","author":"Cortellini","year":"2019","journal-title":"Oncologist"},{"issue":"11","key":"10.1016\/j.jgo.2026.102971_bb0105","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1002\/cncr.30642","article-title":"Immune checkpoint inhibitors in challenging populations","volume":"123","author":"Johnson","year":"2017","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.jgo.2026.102971_bb0110","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1002\/art.41068","article-title":"Safety and efficacy of immune checkpoint inhibitors in patients with cancer and preexisting autoimmune disease: a nationwide, multicenter cohort study","volume":"71","author":"Tison","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jgo.2026.102971_bb0115","series-title":"ClinicalTrials.gov identifier: NCT03656627. Nivolumab in patients with advanced non-small cell lung cancer and pre-existing autoimmune disease","author":"U.S. National Library of Medicine","year":"2026"},{"key":"10.1016\/j.jgo.2026.102971_bb0120","author":"U.S. National Library of Medicine"},{"issue":"1","key":"10.1016\/j.jgo.2026.102971_bb0125","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"10.1016\/j.jgo.2026.102971_bb0130","first-page":"1507","article-title":"Prevalence of autoimmune disease among patients with lung cancer: implications for immunotherapy treatment options. JAMA","volume":"2","author":"Khan","year":"2016","journal-title":"Oncol"},{"key":"10.1016\/j.jgo.2026.102971_bb0135","author":"American cancer society"},{"key":"10.1016\/j.jgo.2026.102971_bb0140","author":"SEER-Medicare Linked Data Resource"},{"key":"10.1016\/j.jgo.2026.102971_bb0145","author":"NCI SEER Training Modules"},{"issue":"12","key":"10.1016\/j.jgo.2026.102971_bb0150","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1001\/jamaoncol.2021.4932","article-title":"Update of incidence, prevalence, survival, and initial treatment in patients with non-small cell lung cancer in the US","volume":"7","author":"Ganti","year":"2021","journal-title":"JAMA Oncol"},{"issue":"5","key":"10.1016\/j.jgo.2026.102971_bb0155","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1002\/cncr.32624","article-title":"Real-world use and survival outcomes of immune checkpoint inhibitors in older adults with non-small cell lung cancer","volume":"126","author":"Youn","year":"2020","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.jgo.2026.102971_bb0160","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1093\/gerona\/glx229","article-title":"Measuring frailty in Medicare data: development and validation of a claims-based frailty index","volume":"73","author":"Kim","year":"2018","journal-title":"J Gerontol A Biol Sci Med Sci."},{"issue":"36","key":"10.1016\/j.jgo.2026.102971_bb0165","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of Immune-Related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.jgo.2026.102971_bb0170","doi-asserted-by":"crossref","DOI":"10.1007\/s11912-020-0897-9","article-title":"Immune-related adverse events (irAEs): diagnosis, management, and clinical pearls","volume":"22","author":"Darnell","year":"2020","journal-title":"Curr Oncol Rep."},{"issue":"5","key":"10.1016\/j.jgo.2026.102971_bb0175","doi-asserted-by":"crossref","first-page":"e783","DOI":"10.1016\/j.cllc.2018.05.016","article-title":"Real-world treatment patterns, overall survival, and occurrence and costs of adverse events associated with second-line therapies for medicare patients with advanced non-small-cell lung cancer","volume":"19","author":"Arunachalam","year":"2018","journal-title":"Clin Lung Cancer"},{"issue":"2","key":"10.1016\/j.jgo.2026.102971_bb0180","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1524-4733.2009.00671.x","article-title":"Use of stabilized inverse propensity scores as weights to directly estimate relative risk and its confidence intervals","volume":"13","author":"Xu","year":"2010","journal-title":"Value Health"},{"issue":"3","key":"10.1016\/j.jgo.2026.102971_bb0185","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"issue":"12","key":"10.1016\/j.jgo.2026.102971_bb0190","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.21037\/atm-20-8124","article-title":"Safety of immune checkpoint inhibitors in patients with cancer and pre-existing autoimmune disease","volume":"9","author":"Alexander","year":"2021","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.jgo.2026.102971_bb0195","article-title":"Multidisciplinary approach to treatment with immune checkpoint inhibitors in patients with HIV, tuberculosis, or underlying autoimmune diseases","volume":"9","author":"Aguilar-Company","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jgo.2026.102971_bb0200","article-title":"Effectiveness and safety of immune checkpoint inhibitors in cancer patients with autoimmune disease: a retrospective cohort study","author":"Raghavan","year":"2023","journal-title":"J Immunother"},{"key":"10.1016\/j.jgo.2026.102971_bb0205","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.lungcan.2019.05.029","article-title":"Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis","volume":"134","author":"Dafni","year":"2019","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1016\/j.jgo.2026.102971_bb0210","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/cncr.31105","article-title":"Immune checkpoint inhibitors in advanced non-small cell lung cancer","volume":"124","author":"Assi","year":"2018","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.jgo.2026.102971_bb0215","doi-asserted-by":"crossref","first-page":"e274","DOI":"10.1016\/S2665-9913(23)00064-4","article-title":"Mortality and immune-related adverse events after immune checkpoint inhibitor initiation for cancer among patients with pre-existing rheumatoid arthritis: a retrospective, comparative, cohort study","volume":"5","author":"KR","year":"2023","journal-title":"Lancet Rheumatol"},{"issue":"6","key":"10.1016\/j.jgo.2026.102971_bb0220","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1634\/theoncologist.2016-0390","article-title":"Inflammatory arthritis: a newly recognized adverse event of immune checkpoint blockade","volume":"22","author":"Naidoo","year":"2017","journal-title":"Oncologist"},{"issue":"7","key":"10.1016\/j.jgo.2026.102971_bb0225","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1002\/art.27500","article-title":"The programmed death 1\/programmed death ligand 1 inhibitory pathway is up-regulated in rheumatoid synovium and regulates peripheral t cell responses in human and murine arthritis","volume":"62","author":"Raptopoulou","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jgo.2026.102971_bb0230","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1186\/s13075-015-0859-z","article-title":"Soluble PD-1 aggravates progression of collagen-induced arthritis through th1 and th17 pathways","volume":"17","author":"Liu","year":"2015","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"10.1016\/j.jgo.2026.102971_bb0235","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1007\/s40266-021-00899-7","article-title":"Safety and effectiveness of immune checkpoint inhibitors in older patients with cancer: a systematic review of 48 real-world studies","volume":"38","author":"Luciani","year":"2021","journal-title":"Drugs Aging"}],"container-title":["Journal of Geriatric Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406826001256?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406826001256?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:04:39Z","timestamp":1777593879000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879406826001256"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1879406826001256"],"URL":"https:\/\/doi.org\/10.1016\/j.jgo.2026.102971","relation":{},"ISSN":["1879-4068"],"issn-type":[{"value":"1879-4068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and effectiveness of immune checkpoint inhibitors in older adults with metastatic non-small cell lung cancer and pre-existing autoimmune disease \u2013 A SEER-Medicare study","name":"articletitle","label":"Article Title"},{"value":"Journal of Geriatric Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgo.2026.102971","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102971"}}